Division of Nephrology, Department of Medicine, Bone and Mineral Metabolism, University of Kentucky, Lexington, Kentucky, United States of America.
Division of Healthcare Outcomes and Optimal Patient Services, Department of Surgery, University of Kentucky, Lexington, Kentucky, United States of America.
PLoS One. 2022 Jul 19;17(7):e0271555. doi: 10.1371/journal.pone.0271555. eCollection 2022.
Osteoporosis treatment usually starts with an antiresorber and switches to an anabolic agent if it fails. It is known that suppressing bone resorption also results in reduced bone formation. In addition, patients with prior treatment with antiresorbers may have reduced response to subsequent anabolic treatment. This study determined the prevalence of low bone formation in untreated osteoporosis patients to identify patients who may not be optimally treated under the current paradigm.
This is a cross-sectional study of bone samples stored in the Kentucky Bone Registry. Included samples were from adult patients presenting for workup of osteoporosis. Exclusion criteria were other diseases or treatments affecting bone. Patients underwent iliac crest bone biopsies after tetracycline labeling for identification of bone formation.
107 patients met study criteria, 92 White and 5 Black women and 10 White men. Forty percent of patients (43/107) had low bone formation/bone surface (BFR/BS < 0.56 mm3/cm2/yr). Clinical and serum parameters did not differ between formation groups, except for type II diabetes, which was found exclusively in the low formation group.
Starting treatment of osteoporotic patients with an antiresorber in all patients appears not optimal for a significant portion.
骨质疏松症的治疗通常从使用抗吸收剂开始,如果治疗失败,则转而使用合成代谢药物。已知抑制骨吸收也会导致骨形成减少。此外,先前使用抗吸收剂治疗的患者可能对随后的合成代谢治疗反应降低。本研究旨在确定未接受治疗的骨质疏松症患者中低骨形成的患病率,以确定在当前范式下可能未得到最佳治疗的患者。
这是一项对储存在肯塔基州骨骼登记处的骨骼样本进行的横断面研究。纳入的样本来自因骨质疏松症就诊的成年患者。排除标准为其他影响骨骼的疾病或治疗。在四环素标记后,患者接受了髂嵴骨活检以确定骨形成。
107 名患者符合研究标准,其中 92 名白人女性和 5 名黑人女性,以及 10 名白人男性。40%的患者(43/107)存在低骨形成/骨表面(BFR/BS<0.56mm3/cm2/yr)。形成组之间的临床和血清参数没有差异,除了 2 型糖尿病,这种疾病仅存在于低形成组。
对所有患者都开始使用抗吸收剂治疗骨质疏松症患者似乎并不适合很大一部分患者。